Hemispherx Biopharma (HEB) Could Continue Wild Trading On Russell Index Addition
Tweet Send to a Friend
With an FDA decision still pending on its Ampligen drug, trading in Hemispherx Biopharma, Inc. (NYSE: HEB) is volatile on ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
